Hisamitsu Pharmaceutical Co (FSE:4530) Cyclically Adjusted PS Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FSE:4530 Hisamitsu Pharmaceutical Co Inc FSE:4530
89 GF Score
Price 円3,975.00
GF Value 円3,237.07
View Full Analysis

What is Hisamitsu Pharmaceutical Co Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Hisamitsu Pharmaceutical Co  (FSE:4530) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Hisamitsu Pharmaceutical Co Cyclically Adjusted PS Ratio Related Terms


Hisamitsu Pharmaceutical Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Hisamitsu Pharmaceutical Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hisamitsu Pharmaceutical Co Cyclically Adjusted PS Ratio Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.92 2.87 2.33 2.24 2.08

Hisamitsu Pharmaceutical Co Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.24 2.20 2.09 2.07 2.07

FSE:4530 vs AMPH, ESPR, NIKA: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hisamitsu Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Hisamitsu Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


FSE:4530
89GF Score
Hisamitsu Pharmaceutical Co Inc FSE:4530
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hisamitsu Pharmaceutical Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Hisamitsu Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Feb. 2026 is calculated as:

For example, Hisamitsu Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Feb. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Feb. 2026 (Change)*Current CPI (Feb. 2026)
=684.496/112.2000*112.2000
=684.496

Current CPI (Feb. 2026) = 112.2000.

Hisamitsu Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201605 450.443 98.200 514.661
201608 426.850 97.900 489.199
201611 415.793 98.600 473.144
201702 432.629 98.100 494.811
201705 430.983 98.600 490.429
201708 446.505 98.500 508.608
201711 431.012 99.100 487.987
201802 457.535 99.500 515.934
201805 400.055 99.300 452.026
201808 428.502 99.800 481.743
201811 396.522 100.000 444.898
201902 490.931 99.700 552.482
201905 353.260 100.000 396.358
201908 413.224 100.000 463.637
201911 434.515 100.500 485.100
202002 513.252 100.300 574.146
202005 304.248 100.100 341.025
202008 342.907 100.100 384.357
202011 341.074 99.500 384.608
202102 411.896 99.800 463.073
202105 339.418 99.400 383.126
202108 376.461 99.700 423.660
202111 344.696 100.100 386.363
202202 416.718 100.700 464.307
202205 330.748 101.800 364.538
202208 416.335 102.700 454.847
202211 404.665 103.900 436.991
202302 466.120 104.000 502.872
202305 412.487 105.100 440.352
202308 448.701 105.900 475.394
202311 470.008 106.900 493.311
202402 513.301 106.900 538.750
202405 477.257 108.100 495.358
202408 540.295 109.100 555.647
202411 488.160 110.000 497.923
202502 610.072 110.800 617.780
202505 474.548 111.800 476.246
202508 558.187 112.100 558.685
202511 558.363 113.200 553.430
202602 684.496 112.200 684.496

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?

Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued. The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.

Key valuation signals for FSE:4530:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
  • GF Score™: 89/100

No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hisamitsu Pharmaceutical Co Business Description

Other Exchanges HTSUY:USA
Address 408 Tashiro Daikancho, Saga Prefecture, Tosu, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score

Get the complete analysis for FSE:4530

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円3,975.00
Price
円3,237.07
GF Value